Replies to post #163693 on Biotech Values

[oc631]

ENTA’s risk/reward tradeoff is favorably skewed at the current valuation to an uncommon degree.

Right. I agree that ENTA is a good value at this level. I just wanted to point out simeprevir may find wider uses within niche markets.